Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study

American Heart Journal

Volumn 142, Issue 6, 2001, Pages 952-959

  Bittl, John A ^a,d   Chaitman, Bernard R ^b,d   Feit, Frederick ^c,d   Kimball, William ^d   Topol, Eric J ^d,e  

^a Munroe Regional Med Center   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d IQVIA   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; HIRULOG;

AGED; ARTICLE; BLEEDING; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORONARY STENT; DOUBLE BLIND PROCEDURE; DRESSLER SYNDROME; DRUG EFFICACY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0035206428     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2001.119374     Document Type: Article

References (30)

1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
2. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial
3. The ESPRIT study: A randomised, placebo-controlled trial of a novel dosing regimen of eptifibatide in planned coronary stent implantation
4. Defining the optimal ACT during percutaneous coronary intervention: Aggregate results from six randomized controlled trials
5. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor
6. Heparin neutralization by platelet-rich thrombi: Role of platelet factor 4
7. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
8. Relation between activated clotting lime during angioplasty and abrupt closure
9. Length of hospital stay and complications after percutaneous transluminal caronary angioplasty: Clinical and procedural predictors
10. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO): Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators
11. Clinical outcomes of bivalirudin for acute coronary syndromes
12. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty
13. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina
14. Guidelines for percutaneous transluminal coronary angioplasty: A report of the American Heart Association/American College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures
15. Myonecrosis after revascularization procedures
16. Antithrombotic therapy in patients undergoing coronary angioplasty
17. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study: A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALK)
18. Recombinant hirudin for unstable angina pectoris: A multicenter, randomized angiographic trial
19. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial
20. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: A randomised trial
21. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty
22. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis
23. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial
24. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
25. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes
26. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor
27. Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty
28. Relation between the risk of abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty
29. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin
30. Kinetic mechanism for the interaction of hirulog with thrombin